Compassionate Use of Pirtobrutinib for a Patient with Waldenstrom s macroglobulinemia

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1. CLL/SLL and have received all 5 classes of available therapy: chemotherapy, anti-cd-20 antibody, covalent Bruton’s Tyrosine Kinase (BTK) inhibitor, BCL-2 inhibitor and PI3K inhibitor;
    2. 2. MCL, who has been previously treated with a co

You may not be eligible for this study if the following are true:

  • If you do not meet the inclusion criteria.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.